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Abstract
Background: There is increasing evidence that community-based treatment of drug resistant tuberculosis (DRTB) is
a feasible and cost-effective alternative to centralized, hospital-based care. Although several large programs have
reported favourable outcomes from community-based treatment, to date there has been no systematic assessment
of community-based DRTB treatment program outcomes. The objective of this study was to synthesize available
evidence on treatment outcomes from community based multi-drug resistant (MDRTB) and extensively drug
resistant tuberculosis (XDRTB) treatment programs.
Methods: We performed a systematic review and meta-analysis of the published literature to examine treatment
outcomes from community-based MDRTB and XDRTB treatment programs. Studies reporting outcomes from
programs using community-based treatment strategies and reporting outcomes consistent with WHO guidelines
were included for analysis. Treatment outcomes, including treatment success, default, failure, and death were
pooled for analysis. Meta-regression was performed to examine for associations between treatment outcomes
and program or patient factors.
Results: Overall 10 studies reporting outcomes on 1288 DRTB patients were included for analysis. Of this
population, 65% [95% CI 59-71%] of patients had a successful outcome, 15% [95% CI 12-19%] defaulted, 13%
[95% CI 9-18%] died, and 6% [95% CI 3-11%] failed treatment for a total of 35% [95% CI 29-41%] with unsuccessful
treatment outcome. Meta-regression failed to identify any factors associated with treatment success, including study
year, age of participants, HIV prevalence, XDRTB prevalence, treatment regimen, directly observed therapy (DOT)
location or DOT provider.
Conclusions: Outcomes of community-based MDRTB and XDRTB treatment outcomes appear similar to overall
treatment outcomes published in three systematic reviews on MDRTB therapy. Work is needed to delineate
program characteristics associated with improved treatment outcomes.
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Background
Drug resistant tuberculosis (DRTB) is a global health con-
cern that undermines recent successes in tuberculosis
(TB) control [1]. DRTB includes both multidrug-resistant
(MDR) and extensively drug-resistant (XDR) TB; MDRTB
strains are resistant to the two most-effective first-line
anti-TB drugs, while XDRTB is resistant to four highly
effective anti-TB drugs [2]. Worldwide there are approxi-
mately 650,000 cases of MDRTB of which 10% are
XDRTB [3,4]. Without significant scale-up in diagnostic
and treatment capacity for DRTB, MDRTB and XDRTB
could become the dominant forms of TB worldwide [1].
Treatment of MDRTB and XDRTB requires second-
line anti-TB drugs that are more costly, less effica-
cious and more toxic than first-line drugs [4,5], and
require ≥20 months of medical therapy [6]. Treatment
is typically delivered using the WHO DOTS-Plus model
and traditionally involves prolonged inpatient treatment
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that enables enhanced monitoring of adverse drug reac-
tions, ensures adherence, and may prevent spread within
the community [7,8]. Unfortunately, resource limitations
often force patients to wait months for inpatient therapy,
during which time they can spread to other people in their
community. Inpatient therapy also increases the risk of
nosocomial transmission, particularly in low-resource
settings.
To address these challenges, many DRTB treatment
programs have incorporated community participation in
the DRTB treatment. Community-based directly observed
therapy (cb-DOTS) programs are low-cost treatment
programs that utilize family members, neighbours, co-
workers, local health care workers (HCWs) or former pa-
tients to directly observe treatment rather than requiring
hospitalizations or frequent visits to a health care facility.
For drug-susceptible TB, cb-DOTS appears comparable or
better than hospital-based approaches [9-11]. Many re-
search groups have examined treatment outcomes of
community-based DRTB treatment models and report
good results, however to date no systematic evaluation of
cb-DRTB programs has been reported in the literature.
Our objective was to synthesize available evidence on
treatment outcomes from community based multi-drug
resistant (MDRTB) and extensively drug resistant tubercu-
losis (XDRTB) treatment programs.
We performed a systematic review and meta-analysis
to investigate treatment outcomes in community-based
MDRTB and XDRTB treatment programs. For the pur-
pose of this study, community-based refers to treatment
that occurs on an outpatient basis, and includes partici-
pation by community members in treatment delivery.
Treatment outcomes were examined and pooled for ana-
lysis. Program and patient characteristics were also ana-
lyzed to determine the effect these variables had on
treatment success.
Methods
The present review have been reported according to the
preferred reporting items for systematic reviews and
meta-analyses (PRISMA) (Additional file 1).
Search strategy
A methodical strategy was used to identify relevant publi-
cations. Our search strategy was modeled after Johnston
et al. [12] and Orenstein et al. [13] with slight modifica-
tion. The search was limited to English language pub-
lications in the EMBASE, MEDLINE, International
Pharmaceutical Abstracts and BIOSIS databases and the
Web of Science that were published between January
1990 and August 2012. Keyword searches were conducted
on both titles and abstracts to identify relevant publica-
tions using combinations of the keywords “MDR*”,
“XDR*”, “drug resistant”, “drug-resistant”, “multidrug”,
“multi-drug”, “extensively”, “TB”, “tuberculosis”, “directly
observed”, “DOTS”, “DOTS-Plus”, “cb-DOTS”, “treat-
ment”, “community”, “outpatient”, “public participation”,
“community-based”, “decentralized”, “home-based”, “am-
bulatory”, “clinic”, “community health worker”, and
“CHW”. A search of EBM reviews was also conducted to
determine existing systematic reviews on this topic. This
included Database of Abstracts of Reviews and Effects,
Cochrane Central Register of Controlled Trials and
Cochrane Database of Systematic Reviews. Citations
were all thoroughly reviewed and it was determined that
no systematic reviews were published on this subject.
Online archives of several journals were also methodically
searched manually from January 1990 (when available).
Journals searched included American Journal of Respira-
tory and Critical Care Medicine, Clinical Infectious
Disease, Chest, International Journal of Tuberculosis and
Lung Disease, and Journal of Infectious Disease. Biblio-
graphic searches of identified articles were conducted to
identify other relevant studies.
Selection of studies
Relevant articles were reviewed and examined for eligi-
bility beginning with the abstract and followed by full
text review. The following inclusion criteria were ap-
plied: original study; published in English after January
1990; reported treatment outcomes on patients with
culture-confirmed MDRTB or XDRTB; utilized directly
observed treatment on an outpatient basis; employed
community-based treatment strategies; reported treat-
ment outcomes that would allow for comparison with
other studies. Studies were excluded if they utilized only
surgical interventions, reported only preliminary out-
comes, routinely hospitalized patients for ≥ six months,
or did not report data in a format enabling extraction.
Methodological assessment
Two authors (P.W. and J.J.) independently assessed the
methodological quality of the selected studies considered
in the current review. Randomized controlled-trials, pro-
spective cohorts, retrospective cohorts or consecutive
case control studies were assessed. Publications included
in this analysis reported treatment outcomes for ≥ five
patients, reported results on at least 50% of patients, re-
ported general demographic information on patients,
and included community-based treatment ≥ six months
in duration and total treatment duration of ≥18 months.
In the case of duplicate data, the publication with the
more detailed reports on treatment outcomes was in-
cluded for meta-analysis. Studies were selected by one
author (P.W.), with selected studies reviewed for inclu-
sion/exclusion by two authors (P.W, J.J.).
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Treatment outcome definitions
We used treatment outcome measures defined by Laserson
et al. and the WHO [5,14]. Patients that met the criteria for
cure or treatment completed were classified as having suc-
cessful treatment outcomes. Patients that met criteria for
death, treatment default, treatment failure or transfer out
were classified as having unsuccessful treatment outcomes.
For data analysis, patients whose results were not available
or patients that met transfer out criteria were placed in the
treatment default category.
Study characteristics
The association between treatment success and several
study characteristics was examined among several sub-
groups. Factors examined included study year (enroll-
ment started before 2002 versus after 2002), patient age
(>14 years versus ≤14), HIV prevalence (in the cohort
described) (0-2%; >2%), XDRTB infection (0%; >0%),
treatment regimen (individualized; standardized), DOT
location (home-based; clinic/PHC-based) and DOT pro-
vider (CHWs/HCWs only; included family/friends).
Data analysis
Data extraction was performed by one author (P.M.) and
cross-checked by a second author (J.J.). Data was ana-
lyzed using Microsoft Excel (version 14 · 1 · 0) and Stats-
Direct (version 2 · 7 · 9) and STATA/IC v12 · 0. Treatment
outcome data (successful, default, death and failure) across
all studies were pooled to measure overall treatment out-
comes associated with community-based treatment. The
Heterogeneity between these studies was assessed with by
calculating I2 test. A calculated value of I2 > 50% indicated
substantial heterogeneity. For pooling of these results, we
used a more conservative random-effect model. An Egger
test was used to assess for publication bias, and funnel
plots were created.
To examine sources of heterogeneity, a random-effects
meta-regression was performed. The dependent variable
was logit-transformed DRTB treatment success (ES). All
10 studies were included in this analysis. For ES = 0 or 1,
to avoid generating missing data, a small adjustment term
(2n)−1 was applied to the logit-transformation [15]. Stand-
ard errors were adjusted in accordance. This analysis was
based on a significance level at p = 0 · 05. Predictors were
examined using univariate meta-regression models.
Results
Figure 1 shows the study selection process. The initial
database search yielded 584 articles, while manual search
and bibliographic search yielded 33 additional articles.
Of these articles, 103 were retained for full text review;
88 studies were excluded for various reasons, leaving 10
articles for analysis (Figure 1) [16-25]. Overall the dates of
enrollment for studies ranged from 1996–2011 and exam-
ined populations in six different countries (Table 1). Eight
studies were retrospective and two were prospective.
Study heterogeneity
There was a high degree of heterogeneity between stud-
ies. This was not unexpected, as each study differed in
terms of population characteristics and treatment model.
Studies involved a mean 129 participants with a broad
range of sample sizes (5–651) (Table 1). Two studies
only included children under ≤15 years [19,25]. Two
studies reported and included patients infected with
XDRTB, with a mean of 4 · 4% (1–7). Four studies re-
ported and included patients co-infected with HIV, with
a mean of 28 · 2% (1–60). Of the eight studies that re-
ported on previous TB therapy, 94 · 3% (65–100) of pa-
tients received previous treatment. Eight studies reported
on retrospective cohorts, while two studies reported on
prospective cohorts.
In terms of treatment models, six studies utilized an in-
dividualized regimen and four studies utilized a standard-
ized regimen (Table 2). Treatment duration was expressed
in different ways and varied between studies. All studies
except two reported the DOTS location; these two studies
described outpatient treatment. The other studies involved
treatment at local health centers or decentralized clinics,
local hospitals or in patient homes. The DOTS provider
was reported in all studies and consisted of CHWs,
HCWs, local nurses, friends, neighbours or household
members. Some studies reported additional community
involvement in the form of community education and
support programs, the nomination of treatment support
individuals and community teams that tracked patients
and did home visits if any treatments were missed.
Treatment outcomes
Overall, the 10 studies examined the treatment outcomes
of 1288 DRTB patients (Table 3; Figure 2). Of this popula-
tion, 65% [95% CI 59-71%] had a successful outcome
(Figure 2). A total of 15% [95% CI 12-19%] of patients
defaulted, 13% [95% CI 9-18%] of patients died, and 6%
[95% CI 3-11%] failed treatment for a total of 35% [95%
CI 29-41%] with an unsuccessful treatment outcome. Het-
erogeneity between studies was high (I2 > 50%) for all
treatment outcomes except default. All pooled treatment
outcome results were statistically significant (p < 0 · 05).
Based on the funnel plot, there was no evidence of publi-
cation bias (Additional file 2) (Egger test p = 0 · 69).
Subgroup treatment success
Treatment success among study subgroups was pooled
and analyzed (Table 4). The univariate meta-regression
analysis was performed to explain the source of hetero-
geneity. Treatment success did not differ significantly
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Table 1 Baseline characteristics of the included studies
Study Location Date Study type* Sample size XDR (%) HIV (%) Previous therapy (%) Mean resistance
Drobac et al [19] Peru 1999-2003 RC 27 - - - -
Joseph et al [17] India 2006-2007 PC 38 0 0 100 3 · 6
Malla et al [22] Nepal 2005-2006 RC 175 - - 93 3 · 7
Mitnick et al. [20] Peru 1996-1999 RC 75 - 1 · 3 100 Median 6
Mitnick et al. [21] Peru 1999-2002 RC 651 7 · 4 1 · 4 65 5 · 3, 8 · 4
Oyieng’o et al. [24] Kenya 2008-2010 RC 8 0 50 100 3 · 1
Satti et al. [25] Lesotho 2007-2011 RC 5 0 60 - 2.8
Singla et al. [16] India 2002-2006 RC 126 - 0 100 3
Thomas et al. [18] India 1999-2003 PC 66 1 · 5 - 100 3 · 4
Tupasi et al. [23] Philippines 1999-2002 RC 117 - - 96 -
*RC = retrospective cohort; PC = prospective cohort.
Figure 1 Literature search and study selection process.
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based on study year, age of participants, HIV prevalence,
XDRTB prevalence, treatment regimen, DOTS location
or DOT provider (Additional file 3).
Discussion
Over the past decade, evidence has amassed from treat-
ment programs in low-income regions to demonstrate
the feasibility, safety and cost-effectiveness of cb-DRTB
therapy. Our findings provide further evidence to sup-
port this once controversial model of care. Overall, treat-
ment success was 65% [95% CI 59–71] in a population
of MDRTB and XDRTB patients. The results from this
study are comparable to outcomes reported in two pre-
vious meta-analyses of published MDRTB literature and
one individual patient data meta-analysis (Figure 2)
[12,13,26]. When compared with all treatment outcomes






DOTS location DOTS provider Additional
community
involvement
Drobac et al. [19] I 18-24 n/a Local health centre CHWs, nurses CHWs provided doses
outside centre hours




Malla et al. [22] S 8-12,16-24 5,4 Decentralized clinics Health workers Nominated treatment
support person required
Mitnick et al. [20] I Median 23 (0 · 4-35 · 9) Median 6 (5-9) Outpatient CHWs, nurses -
Mitnick et al. [21] I ≥18 ≥5 Health centre or patient home CHWs Group therapy as needed






Satti et al. [25] I ≥18 6 Outpatient CHWs Community team
tracked patients and
provided support
Singla et al. [16] S 6-9, 18 5,3 Peripheral health
centre or patient home
HCW, household member Household member
supervised evening dose






Tupasi et al. [26] I ≥6, ≥18 5, 4 Local health centre,
or patient home
HCWs Treatment partner
nominated by the patient
*I = Individualized, S = Standardized.
‡Duration of intensive phase and continuation phase are separated by a comma. Otherwise duration represents length of treatment. †Number of drugs in
intensive and continuation regimens separated by a comma.






Default (n) Death (n) Failure (n)
Drobac et al. [19] 27 21 5 1 0
Joseph et al. [17] 38 25 5 3 5
Malla et al. [22] 175 123 29 14 9
Mitnick et al. [20] 75 55 14 5 1
Mitnick et al. [21] 651 429 70 134 18
Oyieng’o et al. [24] 8 6 0 2 0
Satti et al. [25] 5 5 0 0 0
Singla et al. [16] 126 76 22 24 4
Thomas et al. [18] 66 25 16 8 17
Tupasi et al. [26] 117 71 16 18 12
Summary 129 65% 15% 13% 6%
95% CI - [59-71] [12-19] [9-18] [3-11]
I2 Statistic - 73% 49% 74% 81%
p value - 0.0001 0.0381 <0.0001 <0.0001
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reported by Johnston et al., results were similar for treat-
ment default (15% [95% CI 12–19] versus 13% [95% CI
9–17]), death (13% [95% CI 9–18] versus 11% [95% CI
9–13]) and treatment failure (6% [95% CI 3–11] versus
8% [95% CI 5–11]) [12].
The success of cb-DOTS programs for treatment of
drug-susceptible TB has been the subject of a previous
systematic review. Kangovi et al. evaluated 24 programs
and reported an overall treatment success rate of 80 · 1%
[95% CI 77.1-83.2%] [27]. Their definition for community-
based therapy included DOT by a community member ‘in
a location other than a health facility or TB club’. Our in-
clusion criteria were less rigid and included programs that
delivered medication from health care facilities when asso-
ciated with a form of community support.
More recently, a systematic review by Bassili et al. ex-
amined outcomes in ambulatory MDRTB treatment pro-
grams, comparing outcomes to those from hospital-based
programs [28]. Outcomes were similar between ambula-
tory and hospital-based outcomes. Studies included for re-
view did not maintain a requirement for community
support. Related to inclusion/exclusion criteria, this study
included only 8 studies in the ambulatory care arm, and
did not include large cohorts by Mitnick, Tupasi, Singla
[16,21,23]. In addition, two treatment cohorts, including
the largest analyzed, were from high income countries
[29,30]. Thus, findings from this review may not necessar-
ily reflect the majority of community-based MDR-TB
management.
Study limitations
The programs analyzed in this review varied in terms of
DOT delivery site and community support. DOT sites
included hospitals, clinics, community health centres and
patient homes. Meanwhile, community support varied,
and included intense educational sessions for patients and
families, working with a nominated community support
person, food supplementation, and transportation support.
DOTS delivery was provided by various groups, including
nurses, health care workers (HCWs), community mem-
bers, and family members. The variability in community
delivery and community supports makes the evaluation
Figure 2 Forest plot representing treatment success with results from meta-analyses.
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and comparison of individual community programs diffi-
cult. However, this variability likely stems from the
community-responsive design of such programs, and is
likely essential for the success of cb-MDRTB programs.
We attempted to identify elements of cb-MDRTB pro-
grams associated with improved outcomes, such as DOTS
location or DOTS provider. Based on this analysis, how-
ever, there were no significant associations with improved
treatment outcomes, possibly related to the limited sample
size.
The community impact of cb-MDRTB was difficult to
capture in this study. We captured individual patient out-
comes associated with cb-MDRTB programs, but the ef-
fect of cb-MDRTB on treatment wait times, community
and hospital MDRTB transmission, community engage-
ment and stigma, and overall cost were not analyzed.
These outcomes, however, are beginning to emerge in the
MDRTB literature. For example, in South Africa, Heller
et al. reported decreased waiting times in cb-MDRTB
when compared to a traditional, hospital based program
[31]. Meanwhile, Fitzpatrick and Floyd examined cost-
effectiveness of four MDRTB treatment programs and
found that the cost per DALY averted favours cb-
MDRTB therapy [32]. Further assessments will be re-
quired to better understand the influence of cb-MDRTB
programs on transmission dynamics, community per-
ception, and other population-based aspects of TB con-
trol. In addition, the stability of cb-MDRTB treatment
programs during rapid scale-up will also be an import-
ant issue given the recent expansion in MDRTB point of
care diagnostic capacity [33].
We should emphasize that up to four studies from our
analysis were included in previous systematic reviews,
which partially accounts for their similar outcomes.
These four studies, however, contribute to less than 20%
of the outcomes reported in all previous analyses. We
considered comparing cb-MDRTB studies to studies
reporting on other types of treatment programs. Unfor-
tunately, treatment protocols are not well-described in
most studies, preventing strict classification and com-
parison between treatment programs. In addition, our
inclusion of more recent publications may bias our re-
sults towards improved MDRTB outcomes in this co-
hort. Indeed, our subgroup analysis demonstrates non-
significant improvement in treatment outcomes between
studies starting before and after 2002. However, the five
studies published in or after 2009 did not demonstrate
significant differences in outcomes (data not shown).
Lastly, we were limited by the number of studies avail-
able for analysis; with only ten studies and 1288 patients
available for comparison, subgroup analysis was quite
limited.
Conclusion
In conclusion, this systematic review and meta-analysis of
cb-DRTB therapy demonstrates that the published results
of community-based MDRTB and XDRTB treatment pro-
grams appear to have adequate treatment outcomes.
These results help strengthen the evidence base to support
the WHO’s conditional recommendation for cb-MDRTB
therapy and support recent calls for decentralized
MDRTB care [34]. More research is required to examine
individual and population-based effects of cb-MDRTB
care: How do outcomes from home-based care compare
with clinic-based ambulatory care? What community sup-
ports are essential to maintaining adherence and success-
ful outcomes in financially strapped MDRTB treatment
programs? What aspects of MDRTB diagnosis and treat-
ment can a national TB treatment program safely
decentralize? On a population level the effect of commu-
nity engagement and education should be analyzed more
closely, along with careful epidemiological study on
MDRTB transmission. In our opinion, the call for
Table 4 Treatment success among study subgroups
Subgroups Studies Treatment success
(n) (95% CI)
Year study began
2002 or later 5 68% (59-75)
Before 2002 5 63% (52-73)
Patient’s age
Included patients ≤14 years old 6 67% (54-78)
All patients >14 years old 4 65% (62-68)
HIV prevalence
0-2% 4 72% (61-81)
HIV > 2% 2 85% (55-100)
Not specified or unknown 4 61% (46-75)
XDRTB prevalence
0% 3 75% (55-91)
>0% 2 53% (26-78)
Not specified or unknown 5 67% (61-73)
Treatment model
Individualized 6 65% (54-75)
Standardized 4 66% (60-71)
DOTS location
Included home-based option 4 64% (61-68)
Clinic or public health centre only 4 63% (45-79)
Not specified 2 82% (54-98)
DOTS provider
Family members, neighbours or
household members sometimes utilized
3 62% (55-69)
Only CHWs, HCWs and other
medical practitioners
7 66% (57-74)
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decentralized MDRTB treatment requires a rapid but
well-considered response.
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